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Abstract
Alternatively activated macrophages (AAM) are a key feature Th2 immunity and have been associated with a
variety of roles during helminth infection. The role this cell subset plays in protzoan infection remain relatively
unexplored, herein we describe the effects of a redox enzyme (rTgPrx) derived from Toxoplasma gondii on murine
macrophage phenotype in vitro. RTgPrx has been previously associated with the maintainence of parasite oxidative
balance. Here our experiments show that rTgPrx promotes AAM as indicated by high arginase-1 (arg-1), YM1 and
FIZZ expression via both signal transducer and activator of transcription (STAT)6-dependent and -independent
mechanisms. Additionally rTgPrx treatment reduced caspase-1 activity and IL-1b secretion, while simultaneously
increasing IL-10 release. Furthermore the in vitro replication of T. gondii (RH strain) was enhanced when
macrophages were treated with rTgPrx. This is in contrast with the previously described effects of a Plasmodium
berghei ANKA 2-cys-peroxiredoxin that promotes pro-inflammatory cytokine production. These results highlight the
role of T. gondii derived redox enzymes as important immune modulators and potentially indicate a role for AAM
in modulating immunopathology and promoting parasite replication during T. gondii infection.
Introduction
Infection with the protozoan parasite T. gondii can
occur via the oral route, the foetal-maternal interface, or
by consumption of undercooked meat containing parasi-
tic cysts [1]. Ovine toxoplasmosis is a major loss to the
agricultural industry through foetal loss The outcome of
infection for the unborn lamb during pregnancy is
dependent on whether infection takes place during
early/mid-gestation or late gestation leading to death or
live birth, respectively. At present a commercially avail-
able live vaccine is on the market and is effective at pre-
venting congenital infection in ewes if administered
before pregnancy. Infection via the oral route results in
a highly polarised Th1 cell response, where this
response is uncontrolled it leads to CD4+ dependent
mortality [2]. In response to the strong Th1 response
the parasite forms long-lived tissue bradyzoites which
can become reactivated in immunocompromised
individuals. Reactivation of the cysts within give rise to
toxoplasmic encephalitis (TE) resulting in neuropathol-
ogy [3]. Parasite and host survival is mediated by control
of the host immune response through a combination of
mechanisms; these can include generation of T-regula-
tory cells [4], and the production of parasite immuno-
modulators [5]. T. gondii possesses an arsenal of
secreted or injected proteins that can modulate host cell
function. Injection of rhoptry bodies into host cells
allows efficient entry and replication of the parasite [6]
and modulation of type-1 immune response genes [7].
Induction of cellular autophagy is a host defence
mechanism by which parasite replication can be con-
trolled, however it has recently been shown that more
virulent strains of the parasite may also be capable of
subverting this pathway [8].
Macrophages sit at the bridge between innate and
adaptive immunity and they serve a number of functions,
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during protozoan infection controlling parasite replica-
tion is chief amongst them. Modulation of macrophage
functional status to either of the two defined phenotypes
classically activated macrophages (CAM) or AAM [9] by
the parasite may serve to modulate host immunity and
prolong parasite survival. A number of defined T. gondii
pathways exist have been shown to very specifically
modulate host immunity including macrophage functions
and pathways such as STAT and TLR signalling [10].
Helminth peroxiredoxins (Prx) derived from the flukes
Schistosoma mansoni and Fasciola hepatica has been
shown to drive the activation of AAM [11]. These cells
display the characteristic markers of AAM including
upregulated arginase-1 (arg-1), Ym1, FIZZ and also
expressed IL-10. Interestingly in the case of F. hepatica
Prx these effects have been shown to be independent of
enzymatic activity in mouse and ovine macrophages
[11,12]. This is highly suggestive of a dual function for
this class of molecules in helminth parasites. Further-
more the development of AAM has also been linked
with enhanced survival of intracellular pathogens during
a co-infection. Taenia crassieps infected mice which are
subsequently infected with Leishmania major and L.
mexicana display higher Leishmania burdens and these
are localised to AAM within the tissues of these mice
[13]. Recently a 2-cys Prx from P. berghi has been
shown to trigger TLR4 on periteonial macrophages
resulting in the release of pro-inflammatory cytokines
such as tumour necrosis factor (TNF)-a and IL-12p40
[14] these results contrast with the described effects of
helminth anti-oxidants. A T. gondii Prx 1 (TgPrx) has
been cloned [15], and studies have shown that it inter-
acts with a novel T. gondii histone lysine methyltransfer-
ase (KMTox) [16]. This complex was shown to regulate
parasite genes related to antioxidant defences and the
maintenance of cellular homeostasis, defining it as a
functioning anti-oxidant.
Despite the role of TgPrx in maintaining cellular
homeostasis, it is unknown if TgPrx has a function in
the context of host macrophage activation either equal
to that of P. berghi or helminth Prx. Here we have
investigated what if any effect recombinant (r)TgPrx
had on macrophage functions or effector mechanisms.
In this study we provide evidence that rTgPrx can
induce murine AAM markers and enhance secretion of
IL-10. We also found that rTgPrx could negatively
influence the secretion of IL-1b from macrophages.
Ultimately resulting in rTgPrx promoting parasite sur-
vival as judged by replication of T. gondii in treated
cells. This is highly suggestive that rTgPrx may have
acquired/developed additional roles during infection
related to the modulation of host macrophage
function.
Materials and methods
T. gondii strain, culture, and infection of macrophages
T. gondii RH strain was obtained from the ATCC and
maintained in VERO cells as previously described [17].
After 4 days of infection confluent monolayers of host
cells were collected and parasites harvested for infection
of macrophages. For parasite survival assays, host cells
were seeded onto coverslips (Nunc) overnight. Prior to
infection cells were treated overnight with LPS, IL-4 or
rTgPrx as described within the text or below. Parasites
were used at a multiplicity of infection (MOI) of 0.2, 24
hrs following infection coverslips were stained with
Giemsa and the numbers of parasites were counted on a
high power view in 100 cells per treatment.
Recombinant T. gondii Prx
T. gondii Prx coding sequence, accession number
305718, as described elsewhere [15] was used to prepare
recombinant protein [16]. In brief, the coding sequence
was cloned, in frame, into an expression vector and
tagged at the C-terminus with a His6 tag. This plasmid
was expressed in E. coli to produce recombinant pro-
teinthat was purified using nickel affinity chromatogra-
phy. Purified protein was dialysed extensively against
sterile endotoxin-free 1 × D-PBS overnight at 4C. Pro-
tein (200 ug) was then phase separated, as previously
described, to remove contaminating endotoxin [18].
Briefly, protein was mixed with Trition X-114 to a final
concentration of 5% and incubated on ice for 5 min and
then at 37°C for 5 min. Solutions were centrifuged at
5000 × g for 7 s to form two phases. The upper aqueous
phase contained endotoxin free protein. This processed
was repeated with the aqueous phase. Following this the
protein was again dialysed as above and protein concen-
tration was determined using a Nano-drop. Endotoxin
levels as judged by LAL (Lonza) endpoint assay were
below the limits of detect of the assay.
Enzymatic activity was determined by use of rTgPrx in
a DNA nicking assay [19]. rTgPrx was incubated with
DTT (8 mM) and FeCl3 (0.8 mM) for 15 min prior to
adding 300 ng of DNA prepared from the pGEM-T vec-
tor (Promega). As a negative control DTT was omitted
or proteinase K treated rTgPrx was used. Reactions
were incubated for 2.5 h at 37°C and then visualised on
a 1% agarose gel. Enzymatic activity was denoted by
DNA being protected from nicking.2.3 Macrophage cul-
ture and stimulation.
Bone marrow derived macrophages (BMDM) were gen-
erated by culturing cells collected from the femurs of
C57/bl6 mice with M-CSF (Peprotech), 10 ng/mL, sup-
plemented media for seven days with a change of media
on day 3. Recombinant IL-4 (Peprotech) was used at 20
ng/mL, LPS (Sigma-Aldrich) was used at 100 ng/mL, and
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rTgPrx was as either as indicated or 80 μg/mL. For acti-
vation caspase-1 activation and IL-1b secretion monoso-
dium urate, MSU, (Sigma-Aldrich) was used at a
concentration of 150 μg/mL. Following 24 h stimulation
supernatants were collected, centrifuged at 4°C to remove
debris and stored until analysis. Cells were lysed in 0.1%
Trition X-100 for analysis of arginase activ. For later
determination of caspase-1 activity 50 μL of cell lysis buf-
fer (ENZO Lifesciences) was added to each well. To inhi-
bit STAT6 activity leflunomide (Sigma-Aldrich), at a
concentration of 100 μM, was added to cells 30 min prior
to treatment.
Arginase activity, NO, and cytokine measurement
Arginase activity was measured in cell lysates as pre-
viously described and reported as mU/106 cells [20].
NO concentration was measured using the Griess
reagent system (Promega) and results are given as μM.
IL-10, IL-12p40, and IL-1b were measured using ELISA
kits from eBioscience according to the manufacturer’s
instructions, are reported as pg/mL.
Intra-cellular ROS measurement
105 cells were seeded in a sterile 96 well fluorescence plate
(Nunc) overnight to allow adherence. Following this cells
were washed with HBSS and then loaded with 2,
7-Dichlorodihydrofluoresdiacetate (2, 7-DCF) (Cayman
Chemical) at a concentration of 100 μM in DMEM supple-
mented with 1% FCS for 30 min at 37°C. Cells were
washed to remove excess dye and cells were further stimu-
lated for 60 min in HBSS with indicated proteins or cyto-
kines. Fluorescence was then measured with excitation and
emission wavelengths of 500 nm and 530 nm respectively.
Results are reported as arbitrary units (AU) as experimen-
tal readings were normalised to fluorescence readings from
unstimulated cells without 2, 7-DCF treatment.
Caspase-1 activity
Following stimulation cells were lysed in cell lysis buffer
(Enzo Life Sciences) 50 μL/well, this was then added to
50 μL of assay buffer (Enzo Life Sciences) containing
the caspase-1 specific substrate YVAD-AFC (Enzo Life
Sciences) at a final concentration of 50 nM. The reac-
tion was allowed to proceed in fluorescence plates for 2
h at 37°C protected from light. Fluorescence was then
measured at excitation and emission wavelengths of
400 nm and 505 nm, respectively. Results are reported
as pmol of AFC/min/105 cells after comparison to read-
ings taken from a standard curve generated from free
AFC (Enzo Life Sciences).
RNA isolation and gene expression
Expression of Ym1 (chi3l3), FIZZ1 (retln), and arginase-
1 (arg1) genes was analysed by real-time PCR Taqman
assays with reference to HPRT (hprt1) as a house-keep-
ing control. Taqman assays were from ABI Systems and
as follows; Mm00475988 m1 for arg1, Mm04213363 u1
for chi3l3, Mm00445109 m1 for retlna, and m1 for
HPRT. were stimulated as above and incubated for 16
hrs, thereafter monolayers were washed once with ice-
cold D-PBS (Sigma-Aldrich) and Tri-reagent (Sigma-
Aldrich) was added, cell lysates containing RNA were
then stored -80°C. RNA was extracted by the Phenol-
Chloroform method and quantified using a Nano-drop.
Reverse transcription was performed using GoScript
Reverse Transcription System from Promega. Taqman
assays were performed on a Roche Lightcycler. Results
are reported as expression levels were calculated using
the Δct method relative to HPRT.
Statistical analysis
Data presented is the mean ± SD of triplicate measure-
ments and is representative of at least three independent
experiments. Data were analysed using GraphPad Prism
and the ANOVA test. A p value < 0.05 was considered
to be statistically significant.
Results
Alternative activation of murine macrophages by rTgPrx
BMDM were used to determine the effects of rTgPrx on
macrophage activation status - cells were incubated for
24 h with increasing doses of rTgPrx. Thereafter intra-
cellular arginase activity was determined; levels of argi-
nase activity increased following treatment with either
40 μg/mL or 80 μg/mL of rTgPrx (Figure 1a). Arginase
activity was not significantly different between cells trea-
ted with 40 μg/mL of rTgPrx or 20 ng/mL of IL-4. NO
concentration in the supernatants of the same cells was
determined and even cell treated with the highest levels
of rTgPrx (80 μ/mL) produced little NO (Figure 1b). IL-
12p40 considered a key pro-inflammatory cytokine pro-
duced by CAMF and examination of the rTgPrx stimu-
lated cells revealed no upregulation of IL-12p40 at the
protein level in comparison to LPS stimulated cells
which produced 571.1 ± 20.75 pg/mL (Figure 1d). Simi-
larly IL-10 has been linked to suppressive or AAMF
[21]. IL-4 and LPS induced IL-10 levels above those of
the controls but these were not statistically significant.
However incubation of cells with rTgPrx induced
roughly a 6-fold increase in IL-10 protein levels over
control cultures and levels were significantly greater in
comparison with other treatments (Figure 1d). We next
conducted real-time to examine the expression of genes
associated with AAMF, namely Ym1 and FIZZ1 [9].
Using IL-4 as a positive control an upregulation of
FIZZ, Ym1, and arg-1 was noted in cells (Figures 1e,
f and 1g). When cells were activated with rTgPrx an
upregulation of these gene was also seen to occur
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Figure 1 Activation of murine macrophages by rTgPRX. Cells were stimulated for 24 h under the indicated conditions and then analysed. (A)
Cell lysates were tested for arginase activity by enzyme assay. (B) NO was measured in the supernatants from the same cultures as in (A). IL-
12p40 (C) and IL-10 (D) were measured by ELISA in supernatants. PCR (E - G) was performed on cell 16 h after stimulation for FIZZ (E), Ym1 (F),
and Arg-1 (G). rTgPrx at 80 μg/mL was used in panels (b), (c), and (d). p < 0.05 and ***p < 0.001, values represent a mean of triplicate wells ±
SD; experiments were repeated three times with similar results.
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(Figures 1e, f and 1g) suggesting a strong alternative
activation profile in rTgPrx exposed macrophages.
Experiments performed in cells treated with polymyxin
B and rTgPrx simultaneously indicate that the above
effects are not due to LPS contamination (additional file
1).
STAT6 dependent and independent features of rTgPrx
activated macrophages
STAT6 is a key transcription factor key to the initiation
of Th2 immune responses in a number of cellular com-
partments, including T-cells and macrophages and acts
downstream of IL-4 signalling [22]. Using a previously
verified chemical inhibitor, leflunomide, of STAT6 [23]
we examined whether the effects of rTgPrx were depen-
dent or independent of STAT6. STAT6 inhibition in
macrophages prior to treatment with IL-4 resulted in
reduced levels of arg-1 and IL-10 protein levels (Figures
2a and 2b). Real-time PCR revealed that upregulation of
FIZZ, Ym1, and arg-1 expression levels by IL-4 priming
was prevented in the presence of the STAT6 inhibitor
(Figures 2c-e). Treatment of macrophages with inhibitor
prior to rTgPrx activation resulted in no change in IL-
10 levels but a significant decrease in arginase levels
(Figures 2a and 2b). Furthermore when the level of arg-
1 expression was examined it too was found to be
decreased in the presence of the STAT6 inhibitor. Sig-
nificantly there was no reduction in Ym1 and FIZZ
levels within the inhibitor treated rTgPrx activated-
macrophages (Figures 2c-e). This reveals a differential
control mechanism of genes involved in alternative
activation induced by rTgPrx.
Alteration of intra-cellular ROS levels and caspase-1
activation of IL-1b by rTgPrx
Prx enzymes act to scavenge oxygen radicals and pre-
vent cellular damage. Therefore, we sought to determine
if rTgPrx could alter the intracellular levels of reactive
oxygen species (ROS) in host cells. Using DCF labelling
of cells to monitor ROS levels we found that LPS could
induce ROS levels in comparison to untreated cells (Fig-
ure 3a). When rTgPrx was used in combination with
LPS to stimulate cells there was no significant upregula-
tion in ROS levels, suggesting that rTgPrx maintains an
antioxidant function in the mammalian host cell envir-
onment (Figure 3b). Increases in intracellular ROS,
induced by monosodium urate crystals (MSU), has been
linked to inflammasome activation of IL-1b via caspase-
1 cleavage of the pro-form of IL-1b. Using MSU we sti-
mulated cells to determine if changes in ROS levels
could be detected and further modulated using rTgPrx,
in agreement with our previous findings using LPS we
found that rTgPrx could indeed alter the ROS levels
induced by MSU (Figures 3a and 3b). This effect was
seen only when rTgPrx was used to stimulate cells
simultaneously as MSU and when rTgPrx was at a high
dose of 80 μg/mL but not at 40 μg/mL. Following sti-
mulation with MSU we next measured intra-cellular
caspase-1 enzyme activity, by fluorescent enzyme assay,
and release of IL-1b. We found that MSU stimulation
Figure 2 STAT6 dependent and independent functions of rTgPrx. Cells were treated with the STAT6 inhibitor leflunomide for 30 min prior
to stimulation or with vehicle control. (A) Cell lysates were used to determine the arginase activity by enzymatic assay. (B) IL-10 levels from
supernatants weremeasured by ELISA. (C, D, & E) PCR for FIZZ (C), Ym1 (D), and Arg-1 (E) was carried out on RNA isolated from stimulated cells
after 16 h. ***p < 0.001 values represent a mean of triplicate wells ± SD; experiments were repeated three times with similar results.
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resulted in increased levels of both caspase-1 and IL-1b
levels (Figures 3c and 3e). Using rTgPrx as an antagonist
to MSU we found reductions in both the levels of cas-
pase-1 and IL-1b release (Figures 3d and 3f). Similarly
using LPS as an agonist we found that LPS can induce
ROS and activate the caspase-1/IL-1b pathway and
rTgPrx could act as an antagonist to this effect (addi-
tional file 2).
Pre-treatment of host cells with rTgPrx increases parasite
replication
Macrophages were treated with LPS, IL-4 or rTgPrx
overnight, cells were then infected with tachyzoites (M.
O.I 0.2) of an in vitro adapted of T. gondii strain.
Counts of viable parasites indicated that while LPS trea-
ted cells could control parasite replication in compari-
son to untreated cells, IL-4 treated cells were incapable
Figure 3 Altered intracellular ROS and caspase-1 and secreted IL-1b levels in rTgPrx exposed macrophages. (A & B) Cells were plated in
sterile fluorescence plates overnight prior to stimulation and measurement of intracellular ROS. (C & D) Caspase-1 activity was measured in cells
lysates by fluorescent enzyme assay 24 h after stimulation. (E & F) Mature IL-1b levels in supernatants were 24 determined by ELISA. *p < 0.05,
**p < 0.01, ***p < 0.001, values represent a mean of triplicate wells ± SD; experiments were repeated three times with similar results.
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of restraining parasite replication resulting in significant
increase in parasite number compared to untreated cells
(Figure 4). rTgPrx treated cells were also incapable of
restraining parasite growth resulting in significantly
greater levels of viable parasites compared to infected
cultures of LPS treated and untreated cells, P < 0.001,
with the greatest effect seen at a dose of 160 μg/mL of
recombinant protein (Figure 4).
Discussion
Our data presented here identifies a novel role for the
T. gondii enzyme Prx in modulating macrophage effec-
tor functions by promoting alternative activation of
macrophages and enhanced parasite replication. Expo-
sure to rTgPrx promoted elevated arginase-1 enzyme
activity and mRNA levels. In addition the markers of
alternative activation Ym1 and FIZZ were also upregu-
lated at the mRNA level. The increased expression of
these genes is indicative of alternative activation [9].
Additionally IL-10 synthesis was also increased in cells
treated with rTgPrx, this is a common phenotype of
cells exposed to helminth molecules undergoing alter-
native activation [21]. We determined that the
increased arginase activity caused by rTgPrx was
dependent on STAT6 signalling, a key transcription
factor in the initiation of Th2 responses downstream
of IL-4/IL-13 signalling. However this was the only
effect of rTgPrx that was STAT6-dependent, revealing
differential control mechanisms of genes involved in
alternative activation by rTgPrx. This is in contrast
with traditional alternative activated macrophages
generated by IL-4 conditioning, whereby expression of
arg-1, Ym1, and FIZZ is conditional on STAT6 activa-
tion. More significantly we found that rTgPrx alters
host cell ROS status suggesting that the effects of
rTgPrx is reliant on intrinsic enzyme activity interfer-
ing in the host cell redox pathway to alter intracellular
immunity signalling. We confirmed the need for intrin-
sic enzyme activity by proteinase K treatment of
rTgPrx prior to experiments resulting in a loss of anti-
oxidant function (additional file 3). This alteration may
be responsible for our findings of reduced caspase-1
activation and IL-1b levels. Recently a report has sug-
gested such a link between alterations in cellular redox
status and activation of the NLRP3/caspase-1/IL-1b
inflammasome [24]. Our final finding of increased
parasite replication following pre-treatment of cells
with rTgPrx indicates its role as an immunomodulator
by negatively acting on anti-parasitic macrophage
functions.
The function of alternatively activated macrophages
within helminth parasitic infections is widely studied
and they have been reported to have a number of roles
dependent on model studied, including providing pro-
tection against Heligosomodies polygyrus infection [25],
preventing immunopathology during S. mansoni infec-
tion [26], and controlling Th2 immunity [27,28]. How-
ever in terms of protozoan infections the role of AAM
is an unresolved issue, due to the cytkine milieu that
occurs during this class of infection, i.e. predominately
“Th1” cytokines IL-12/IFN-g, one might expect classi-
cally activated macrophages to dominate. There are
however reports of AAM during infection with Try-
pansome spp., infection of resistant C57 mice with T.
conglesses resulting in a changing CAM to AAM popu-
lation as infection progressed [29]. This change is
thought to reflect a changing need to control parasite-
mia initially and later to dampen inflammation and
protect the host. Ultimately this switch favours host
and parasite survival. To our knowledge the only work
addressing the issue of AAM in T. gondii infection
related to mice with a dominant negative mutation in
the IFN-g receptor in macrophage-lineage cells, thus
making these cells incapable of activating anti-proto-
zoan effector functions [30]. These mice despite show-
ing the expected immune response to T. gondii, were
unable to control parasitemia specifically within
macrophages and as a consequence displayed reduced
survival. Using macrophages unable to alternatively
activate, non-responsive to IL-4, in the non-healing
model of L. major infection in Balb/c mice, there was
a Th2 response generated but effective control of para-
site numbers within macrophages, again reflecting inef-
fectiveness of AAM in terms of controlling protozoan
replication [31]. Taken together these results would
Figure 4 Enhanced parasite replication in rTgPrx treated
macrophages. BMDM were pretreated with LPS, IL-4 or rTgPrx
overnight prior to infection with T. gondii, MOI 0.2. Data represents
quadruplicate counts ± SD, ***p < 0.001.
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suggest that while the presence of AAM could lead to
enhanced mortality during acute infection with some
protozoans, a switch to an AAM phenotype might lead
to control of immunopathology and benefit both host
and parasite long-term. This theory may not fit with
the known course of disease following infection of
ovine hosts with T. gondii. During pregnancy a reacti-
vation of tissue cysts results in massive parasite repli-
cation and pathology at the foetal-maternal interface
resulting in abortion [1]. The prevalent immune envir-
onment during pregnancy would favour AAM or
indeed regulatory macrophages, favouring production
of IL-10 and less pro-inflammatory cytokines, similar
to the kind seen in our experiments. However our
results certainly raise the possibility that rTgPrx may
represent a previously unidentified immunomodulator.
The most pertinent questions surrounding the func-
tion of rTgPrx regards the trafficking of rTgPrx both
inside the parasite and host. Analysis of the protein
sequence reveals no secretion signal peptides and one
must assume the enzyme is not exported from the para-
site. However when initially cloned rTgPrx was found to
be present in both the extra- and intra-cellular forms of
the parasite. Its distribution within the tachyzoite is lim-
ited and was not found to be present in the parasito-
phorous vacuole or parasitophorous vacuole membrane
[15]. Indeed immunolocalisation shows that rTgPrx is
present in the parasite nucleus [15]. It is thought that
under oxidative stress parasite signalling pathways lead
to Prx translocating to the nucleus and forming a com-
plex the KMTox, a histone lysine methyltransferase, to
regulate gene expression. The question as to how
rTgPrx acts on host cells will require further experimen-
tation. However should a parasite become damaged
upon entry to the host cell or as a result of oxidative
damage, it is not inconceivable that cytosolic rTgPrx
make “leak” into the host cell environment.
To conclude our results clearly show that an enzyme,
rTgPrx, derived from T. gondii promotes AAM and
alongside IL-10 secretion via STAT6 dependent and
independent mechanisms, whilst simultaneously down-
regulating IL-1b production via caspase-1. Negative
modulation of the inflammasome has recently been
reviewed in the context of bacterial and viral infection
[32], however results presented here would suggest
exploration of this phenomena in the context of T. gon-
dii infection warrants investigation. The functional rele-
vance of this effect has only been explored in vitro in
the context of parasite replication which is enhanced
after pre-treatment of cells with rTgPrx. However the
role of this protein and rTgPrx induced AAM during T.
gondii infection warrants further in vivo investigation,
the most suitable method being production of a parasite
bearing a mutant Prx.
Additional material
Additional file 1: Addition of polymyxin B to cultures containing
rTgPrx does not affect alternative activation. BMDM were stimulated
in the presence of IL-4, LPS or rTgPrx in the presence of 50 mg/mL of
polymyxin B. 24 h following treatment arginase activity (a), NO (b), and
IL-10 (c) levels were determined. Values represent a mean of triplicate
wells ± SD; experiments were repeated three times with similar results. *
indicates a P value > 0.05 as determined by Anova.
Additional file 2: rTgPrx acts as an antagonist to LPS induced
capase-1 and IL-1b. BMDM were stimulated simultaneously with LPS
and rTgPrx at the indicated doses. 24 h following treatment caspase-1
activity (a) and IL-1b (b) levels were determined. Values represent a mean
of triplicate wells ± SD; experiments were repeated three times with
similar results. * indicates a P value > 0.05, ** P value > 0.01 as
determined by Anova.
Additional file 3: rTgPrx fails to alternatively activate BMDM
following proteinase K treatment. BMDM were stimulated in the
presence PBS or rTgPrx, prior to treatment stimulants were incubated for
30 min with proteinase K. 24 h following treatment arginase activity (a),
NO (b), and IL-10 (c) levels were determined. Values represent a mean of
triplicate wells ± SD; experiments were repeated three times with similar
results. ****indicates a P value > 0.001 as determined by Anova.
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